[Cisplatin-based chemotherapy for advanced basal and squamous cell carcinomas].
The majority of basal cell (BCC) and squamous cell (SCC) carcinomas of the skin are curable by surgery and/or radiation. However, additional therapy is required when the tumor is locally advanced, or has metastasized. 4 men and 4 women (mean age 70, range 49-86) with advanced BCC and/or SCC were treated with cisplatin-based chemotherapy. The disease was local in 4, local with regional lymph node involvement in 2, involved regional lymph nodes in 1 and was local with distant metastases in 1 patient. All were treated with a combination of cisplatin and 5'-fluorouracil. 2 were treated in addition with a combination of cyclophosphamide, doxorubicin, and cisplatin (CAP). Complete pathological response was seen in 2/8 and partial response in 4/8 with an overall response rate of 75%. There was tumor progression in 2. Survival of patients who responded was from 3-47 months (mean 12). The 2 who did not respond to chemotherapy died within 1 and 3 months of treatment. Significant side-effects in 6 included myelotoxicity and transient renal toxicity. We conclude that chemotherapy is effective in advanced BCC and SCC of the skin and may have curative potential when combined with local therapy.
Goldberg
H
H
Oncology Dept., Rambam Medical Center, Haifa.
Tsalik
M
M
Bernstein
Z
Z
Haim
N
N
D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002280:Basal Cell Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002945:Cisplatin / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D016896:Treatment Outcome
D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin; D005472:Fluorouracil